课题基金 / 基金详情

Activation of RIP1 promotes inflammation in atherosclerosis and obesity: a novel target for cardiometabolic diseases.

Activation of RIP1 promotes inflammation in atherosclerosis and obesity: a novel target for cardiometabolic diseases.
RIP1 的激活会促进动脉粥样硬化和肥胖中的炎症：心脏代谢疾病的新靶点。
批准号：
383203
负责人：
Karunakaran Denuja
金额：
$0.07万
依托单位：
University of Ottawa Heart Institute
依托单位国家：
加拿大
项目类别：
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-02-01 至 2019-02-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=383203&lang=en
关键词：
Atherosclerosis Inflammation Insulin Resistance Macrophages Obesity Rip1

项目摘要

项目成果

Karunakaran Denuja的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Chronic activation of the immune system drives inflammation and contributes directly to obesity, insulin resistance and atherosclerosis. Previously, we showed that a pro-inflammatory cell death pathway (aka necroptosis) driven by key molecules, RIP3 and M
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Therapeutic silencing of RIP1 targets inflammatory pathways to significantly reduce atherosclerotic lesions and improves plaque stability in Apoe-/- mice
Atherogenic lipoproteins induce macrophage necroptosis and can be targeted for therapeutic and diagnostic interventions in atherosclerosis
海外基金